Associations between HbA1c and continuous glucose monitoring‐derived glycaemic variables
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aims: To identify clinically useful associations between HbA 1c levels and various continuous glucose monitoring‐derived metrics. Methods: We retrospectively analysed end‐of‐study HbA 1c levels and >2 weeks of continuous glucose monitoring data collected from 530 adults with Type 1 diabetes or insulin‐requiring Type 2 diabetes during four randomized trials. Each trial lasted ≥24 weeks and provided central laboratory end‐of‐study HbA 1c levels and continuous glucose monitoring data from the preceding 3 months. Participants were assigned to groups based on either HbA 1c levels or continuous glucose monitoring‐derived glucose values. Results: HbA 1c was strongly correlated with mean glucose value (r=0.80), time spent with glucose values in the 3.9–10.0 mmol/l range (time in range; r=–0.75) and percentage of glucose values >13.9 mmol/l (r=0.72), but was weakly correlated with the percentage of glucose values <3.9 mmol/l (r=–0.39) or <3.0 mmol/l (r=–0.21). The median percentage of glucose values <3.0 mmol/l was <1.2% (<20 min/day) for all HbA 1c‐based groups, but the median percentage of values >13.9 mmol/l varied from 2.5% (0.6 h/day) to 27.8% (6.7 h/day) in the lowest and highest HbA 1c groups, respectively. More than 90% of participants with either <2% of glucose values >13.9 mmol/l, mean glucose <7.8 mmol/l, or time in range >80% had HbA 1c levels ≤53 mmol/mol (≤7.0%). For participants with HbA 1c ≥64 mmol/mol (≥8.0%), the median time in range was 44%, with 90% of participants having a time in range of <59%. Conclusions: The associations shown in the present study suggest that continuous glucose monitoring‐derived metrics may help guide diabetes therapy intensification efforts in an HbA 1c‐independent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Self-citationGlucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Self-citationHeinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading
Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017) · Diabetes Care · doi:10.2337/dc17-0636 · Cited by 477
The relationship of hemoglobin A1C to time-in-range in patients with diabetes
Vigersky, R. A., & McMahon, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0310 · Cited by 464
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Self-citationCengiz, E., Xing, D., Wong, J. C., Wolfsdorf, J. I., Haymond, M. W., Rewers, A., Shanmugham, S., Tamborlane, W. V., Willi, S. M., Seiple, D. L., et al. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12030 · Cited by 243
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
Cited by
Yapanis, M., James, S., Craig, M. E., O’Neal, D., & Ekinci, E. I. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac034 · Cited by 291
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Positioning time in range in diabetes management
Advani, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05027-0 · Cited by 170
Benefits and limitations of continuous glucose monitoring in type 1 diabetes
Stone, J. Y., & Bailey, T. S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1706482 · Cited by 30
“HbA1c measurements approximate a person’s average blood glucose level over the past 3 months and are often used to guide therapy.”
BackgroundInfluentialBeyond A1C: exploring continuous glucose monitoring metrics in managing diabetes
Friedman, J. G., Coyne, K., Aleppo, G., & Szmuilowicz, E. D. (2023) · Endocrine Connections · doi:10.1530/ec-23-0085 · Cited by 22
Rama Chandran, S., Rahman, N., Gandhi, M., Tan, N. C., Phoon, I. K. Y., Seah, D. E. J., Cheah, M. H., Sek, K., & Gardner, D. S.-L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111678 · Cited by 10
Metadata
- Authors
- Hirsch, I. B., Welsh, J. B., Calhoun, P., Puhr, S., Walker, T. C., & Price, D. A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2019-07-17
- Volume
- 36
- Issue
- 12
- Pages
- 1637-1642
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2954740162
- Cited by
- 62
- References
- 14
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.